Pacific Biosciences of Ca... (PACB)

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Christian O. Henry - President, CEO & Director James R.

PACB stock jumps after Q2 results beat estimates, with narrow losses, rising margins, and strong global demand.

PACB Sales Up 11%

The headline numbers for Pacific Biosciences (PACB) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Stre...

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.2 per share a year ago.

Beyond analysts' top-and-bottom-line estimates for Pacific Biosciences (PACB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for ...

Pacific Biosciences of California (PACB) reached $1.54 at the closing of the latest trading day, reflecting a -6.1% change compared to its last close.

The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.5, representing a +1.35% change from its previous close.

PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset macroeconomic concerns and drive 2025 growth.

Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).